| Literature DB >> 35834478 |
Ryo Yamamoto1, Ryo Takemura2, Asako Yamamoto2, Kazuki Matsumura1, Daiki Kaito1, Koichiro Homma1, Michihiko Wada2, Junichi Sasaki1.
Abstract
BACKGROUND: Rapid deterioration of oxygenation occurs in novel coronavirus disease 2019 (COVID-19), and prediction of mechanical ventilation (MV) is needed for allocation of patients to intensive care unit. Since intubation is usually decided based on varying clinical conditions, such as required oxygen changes, we aimed to elucidate thresholds of increase in oxygen demand to predict MV use within 12 h.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35834478 PMCID: PMC9282654 DOI: 10.1371/journal.pone.0269876
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Fig 1Patient flow diagram.
Among 285 patients with COVID-19 during the study period, 72 adult patients had oxygen therapy and met all the inclusion criteria. A total of 6 patients were intubated on the day of admission, and therefore 66 patients were eligible for this study. Among 2524 oxygen data available in included patients, 689 were excluded from the analyses because they were those after MV initiation. Abbreviations: COVID-19, novel coronavirus disease 2019; MV, mechanical ventilation.
Characteristics of patients with COVID-19 on oxygen therapy.
| Characteristics | Intubation | No intubation | p value | Standardized Difference |
|---|---|---|---|---|
| Case | 11 | 55 | ||
| Age, years, median (IQR) | 75 (67–81) | 64 (54–76) | 0.044 | 0.773 |
| Sex, male, n (%) | 10 (90.9%) | 39 (70.9%) | 0.264 | 0.526 |
| BMI, median (IQR) | 25 (22–26) | 26 (22–29) | 0.265 | 0.378 |
| Comorbidity, n (%) | 4 (36.4%) | 19 (34.5%) | 1.000 | 0.038 |
| COPD | 0 (0.0%) | 2 (3.6%) | ||
| Interstitial pneumonia | 0 (0.0%) | 2 (3.6%) | ||
| Asthma | 0 (0.0%) | 0 (0.0%) | ||
| CHF | 0 (0.0%) | 2 (3.6%) | ||
| CKD | 0 (0.0%) | 0 (0.0%) | ||
| Cirrhosis | 0 (0.0%) | 0 (0.0%) | ||
| Hypertension | 4 (36.4%) | 11 (20.0%) | ||
| Diabetes mellitus | 0 (0.0%) | 6 (10.9%) | ||
| Smoking history, n (%) | 2 (18.2%) | 10 (18.2%) | 1.000 | 0.009 |
| Ct value on RCP for SARS-CoV-2 | 18 (14–24) | 24 (20–31) | 0.002 | 1.042 |
| Treatment, n (%) | ||||
| Corticosteroid | 6 (54.5%) | 22 (40.0%) | 0.507 | 0.294 |
| Tocilizumab | 0 (0.0%) | 8 (14.5%) | 0.334 | 0.582 |
| Remdesivir | 5 (45.5%) | 20 (36.4%) | 0.735 | 0.186 |
| Unfractionated heparin | 8 (72.7%) | 25 (45.5%) | 0.185 | 0.577 |
COVID-19 = Novel coronavirus disease 2019, IQR = interquartile range, COPD = chronic obstructive pulmonary disease, CHF = congestive heart failure, CKD = chronic kidney disease, Ct = cycle of quantification, PCR = polymerase chain reaction, and SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
aWhen multiple samples were obtained at the same time, Ct values were averaged.
Clinical information associated with changes in oxygen demand.
| Intubation within 12 h | No intubation within 12h | p-value | Standardized Difference | |
|---|---|---|---|---|
| Number of data points | 34 | 1801 | ||
| Changes in oxygen demand, L/min/h, median (IQR) | 0.25 (0.00–0.67) | 0.00 (0.00–0.00) | <0.001 | 0.709 |
| Vital signs, median (IQR) | ||||
| Respiratory rate, /min | 21 (16–26) | 18 (16–20) | 0.003 | 0.500 |
| Heart rate, /min | 72 (65–78) | 75 (64–86) | 0.434 | 0.145 |
| SBP, mmHg | 130 (126–134) | 118 (106–130) | <0.001 | 0.766 |
| Days from positive PCR, median (IQR) | 4 (1–9) | 7 (2–16) | 0.002 | 0.713 |
| Days from admission, median (IQR) | 5 (1–15) | 11 (5–45) | 0.005 | 0.534 |
| Duration of treatment, days from, median (IQR) | ||||
| Corticosteroid | 1 (0–5) | 6 (5–20) | 0.009 | 0.826 |
| Tocilizumab | N/A | 3 (0–5) | N/A | N/A |
| Remdesivir | 1 (0–5) | 5 (1–14) | 0.025 | 0.812 |
| Unfractionated heparin | 0 (0–2) | 6 (1–14) | <0.001 | 1.070 |
| Laboratory, median (IQR) | ||||
| CRP | 1.4 (1.0–1.7) | 2.5 (0.9–8.2) | 0.106 | 0.192 |
| D-dimer | 9.2 (4.9–18.8) | 3.6 (1.5–8.1) | <0.001 | 0.885 |
| Glucose | 148 (99–166) | 176 (136–238) | 0.014 | 0.481 |
| Frequency of respiratory distress | 1 (0–2) | 1 (0–2) | 0.108 | 0.289 |
IQR = interquartile range, SBP = systolic blood pressure, PCR = polymerase chain reaction, and CRP = C-reactive protein.
aFrequency of respiratory distress were shown using 0–4 scale.
Fig 2Receiver operating curve for prediction of mechanical ventilation use by changes in oxygen demand.
Changes in oxygen demand to predict MV use within 12 h were evaluated by ROCs in several models as follows: simple model only using increments in oxygen demand (AUC 0.756 [0.662–0.851]); combination model using both amounts and increments in oxygen demand (AUC 0.888 [0.856–0.919]); and a fully adjusted model including amounts and increments in oxygen demand, RR, Ct value of PCR for SARS-CoV-2, and days from positive PCR (0.933 [0.908–0.958]). Abbreviations: ROC, Receiver operating curve; MV, mechanical ventilation; AUC, area under the ROC; RR, respiratory rate; Ct, quantification cycle; PCR, polymerase chain reaction; and SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Accuracy for prediction of MV usage by changes in oxygen demand.
| Model # | Variables in model | AUC | 95% CI | Optimism | Corrected AUC | Sensitivity | Specificity | NPV | PPV |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Changes in oxygen demand | 0.756 | 0.662–0.851 | 0.001 | 0.756 | 69.7% | 81.9% | 99.3% | 6.8% |
| 2 | Amounts and changes of oxygen demand | 0.888 | 0.856–0.919 | 0.002 | 0.885 | 87.9% | 79.6% | 99.7% | 7.5% |
| 3 | Amounts and changes of oxygen demand with other predictors | 0.933 | 0.908–0.958 | 0.005 | 0.924 | 96.8% | 83.5% | 99.9% | 13.5% |
| 4 | Increments in oxygen demand | 0.774 | 0.689–0.860 | 0.001 | 0.775 | 76.7% | 77.2% | 99.3% | 6.8% |
| 5 | Amounts and increments of oxygen demand | 0.873 | 0.834–0.911 | 0.002 | 0.870 | 86.7% | 76.4% | 99.6% | 7.4% |
| 6 | Amounts and increments of oxygen demand with other predictors | 0.927 | 0.897–0.957 | 0.007 | 0.920 | 96.4% | 82.5% | 99.9% | 14.4% |
MV = mechanical ventilation, AUC = area under the receiver operating characteristic curve, CI = confidence interval, NPV = negative predictive value, and PVV = positive predictive value. Sensitivity, specificity, NPV, and PPV were calculated with Youden Index.
aOther predictors included Ct value of polymerase chain reaction (PCR), days from positive PCR, and respiratory rate (RR).
bAnalyses were performed after excluding negative changes in oxygen demand.
Logit-transformed predictive rate for MV usage within 12 h was calculated in each model as follows:
(1) 0.97 × changes in oxygen − 4.19
(2) 0.56 × changes in oxygen + 0.21 × amounts of oxygen − 4.98
(3) 0.54 × changes in oxygen + 0.21 × amounts of oxygen − 0.12 × Ct value − 0.12 × days from PCR + 0.02 × RR − 1.70
(4) 0.95 × changes in oxygen − 4.15
(5) 0.55 × changes in oxygen + 0.20 × amounts of oxygen − 4.87
(6) 0.52 × changes in oxygen + 0.20 × amounts of oxygen − 0.12 × Ct value − 0.14 × days from PCR + 0.01 × RR − 1.47
Fig 3Restricted cubic spline curves and threshold of increments in oxygen demand.
The restricted cubic spline curve was shown for the risks of MV use within 12 h by increments in oxygen demand, with dashed lines for 95% CI. Based on the inflection point, which considers an increase of absolute risk from the baseline by >1% (horizontal dashed line), 0.44 L/min/h of increment in oxygen demand was identified as the threshold to predict mechanical ventilation in the next 12 h. With a higher increment of oxygen than the threshold, the probability of MV use linearly increased. Abbreviations: MV, mechanical ventilation; CI, confidence interval.
Prediction of MV use by increments in oxygen demand in subgroups.
| AUC | 95% CI | Threshold (L/min/h) | Sensitivity | Specificity | NPV | PPV | |
|---|---|---|---|---|---|---|---|
| Age | |||||||
| <65 years | 0.990 | 0.978–1.000 | 0.33 | 66.7% | 88.9% | 99.4% | 8.9% |
| > = 65 years | 0.940 | 0.915–0.966 | 0.50 | 33.3% | 88.4% | 98.2% | 6.3% |
| Amount of oxygen | |||||||
| <4 L/min | 0.990 | 0.978–1.000 | 0.33 | 66.7% | 91.9% | 99.9% | 2.4% |
| > = 4L/min | 0.869 | 0.821–0.918 | 0.40 | 40.7% | 75.6% | 94.9% | 10.3% |
| Respiratory Rate | |||||||
| <20 /min | 0.963 | 0.943–0.983 | 0.75 | 30.8% | 92.9% | 99.1% | 5.1% |
| > = 20 /min | 0.887 | 0.832–0.942 | 0.25 | 64.7% | 81.6% | 97.9% | 14.9% |
| Days from positive PCR | |||||||
| < = 7 days | 0.917 | 0.875–0.958 | 0.33 | 47.8% | 86.4% | 98.2% | 9.7% |
| > 7 days | 0.980 | 0.961–0.999 | 1.00 | 42.6% | 92.6% | 99.3% | 6.0% |
| Viral load | |||||||
| Ct <20 | 0.904 | 0.855–0.954 | 0.22 | 68.4% | 81.4% | 98.2% | 14.6% |
| Ct > = 20 | 0.936 | 0.887–0.984 | 1.00 | 18.2% | 94.2% | 99.0% | 3.4% |
| Frequency of respiratory distress (0–4 scale) | |||||||
| < 2 | 0.918 | 0.877–0.959 | 0.67 | 29.4% | 92.3% | 98.7% | 6.3% |
| > = 2 | 0.953 | 0.908–0.998 | 0.25 | 61.5% | 87.0% | 98.6% | 13.1% |
MV = mechanical ventilation, AUC = area under the receiver operating characteristic curve, CI = confidence interval, NPV = negative predictive value, PVV = positive predictive value, PCR = polymerase chain reaction, and Ct = cycle of quantification.
aThreshold was obtained from an infection point in the spline curve in each subgroup.